US FDA approves Amgen ’s Parsabiv to treat HPT in adult patients
The US Food and Drug Administration (FDA) has approved Amgen ’s Parsabiv (etelcalcetide) to treat secondary hyperparathyroidism (HPT) in adult patients with chronic kidney disease (CKD) on haemodialysis.
Source: Pharmaceutical Technology - Category: Pharmaceuticals Source Type: news